Factors Affecting Opioid Treatment in Cancer Patients

Purpose: Pain is prevalent in cancer patients, appearing to be moderate to severe in more than one third of them. Despite the fact that fentanyl is widely used with effective analgesic results, some patients do not correspond to treatment, resulting in opioid change. Methods: This is a cohort study,...

Full description

Bibliographic Details
Main Authors: Matina Symeonidi, Irene Panagiotou, Eleni Tsilika, Anna Roumeliotou, Antonis Galanos, Kyriaki Mystakidou
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-07-01
Series:Journal of Pharmacy & Pharmaceutical Sciences
Online Access:https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/29396
_version_ 1797728334327578624
author Matina Symeonidi
Irene Panagiotou
Eleni Tsilika
Anna Roumeliotou
Antonis Galanos
Kyriaki Mystakidou
author_facet Matina Symeonidi
Irene Panagiotou
Eleni Tsilika
Anna Roumeliotou
Antonis Galanos
Kyriaki Mystakidou
author_sort Matina Symeonidi
collection DOAJ
description Purpose: Pain is prevalent in cancer patients, appearing to be moderate to severe in more than one third of them. Despite the fact that fentanyl is widely used with effective analgesic results, some patients do not correspond to treatment, resulting in opioid change. Methods: This is a cohort study, performed in Greek patients with cancer. Its scope was to identify potential reasons responsible for opioid change, due to transdermal-fentanyl intolerance, resulting from inadequate analgesia (pain relief<33% in 1week) and/or unacceptable adverse-events (grade≥3 at Common Terminology Criteria-v4.0). The final sample included 289 participants. To investigate responsible reasons for transdermal-fentanyl intolerance we studied its relation with patients’ history, haematology, biochemistry, body-mass-index, demographic and disease related characteristics. The Eastern Cooperative Oncology Group performance status scale, the Mini Mental State Examination questionnaire, the M.D.Anderson Symptom Inventory and the Greek Brief Pain Inventory were also used to measure performance status and quality-of-life for the same reason. Results: Almost one third of the patients had to change to an alternative opioid oral-morphine in order to achieve adequate analgesia or/and avoid adverse-events. The most common adverse-events observed were nausea/vomiting and sleepiness. Statistical analysis demonstrated that younger age (OR=0.976) and obesity (OR=0.29 against underweight, OR=0.39 against normal, OR=0.48 against pre-obese) had a higher possibility to contribute to modification of the analgesic treatment. Furthermore, a higher impact of symptoms in patient’s life (OR=1.184) and chemotherapy (OR=2.109) could also contribute to the need of change of the opioid analgesic medication. Conclusion: This study found significant variables for transdermal-fentanyl intolerance. This knowledge may help person-center care in moderate to severe cancer pain.   This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.
first_indexed 2024-03-12T11:12:33Z
format Article
id doaj.art-5b79b281112b44e986aad23ccc1703d1
institution Directory Open Access Journal
issn 1482-1826
language English
last_indexed 2024-03-12T11:12:33Z
publishDate 2018-07-01
publisher Frontiers Media S.A.
record_format Article
series Journal of Pharmacy & Pharmaceutical Sciences
spelling doaj.art-5b79b281112b44e986aad23ccc1703d12023-09-02T02:37:23ZengFrontiers Media S.A.Journal of Pharmacy & Pharmaceutical Sciences1482-18262018-07-0121110.18433/jpps29396Factors Affecting Opioid Treatment in Cancer PatientsMatina Symeonidi0Irene Panagiotou1Eleni Tsilika2Anna Roumeliotou3Antonis Galanos4Kyriaki Mystakidou5Pain Relief and Palliative Care Unit, Department of Radiology, Areteion Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece.Pain Relief and Palliative Care Unit, Department of Radiology, Areteion Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece.Pain Relief and Palliative Care Unit, Department of Radiology, Areteion Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece.Pain Relief and Palliative Care Unit, Department of Radiology, Areteion Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece.Pain Relief and Palliative Care Unit, Department of Radiology, Areteion Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece.Pain Relief and Palliative Care Unit, Department of Radiology, Areteion Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece.Purpose: Pain is prevalent in cancer patients, appearing to be moderate to severe in more than one third of them. Despite the fact that fentanyl is widely used with effective analgesic results, some patients do not correspond to treatment, resulting in opioid change. Methods: This is a cohort study, performed in Greek patients with cancer. Its scope was to identify potential reasons responsible for opioid change, due to transdermal-fentanyl intolerance, resulting from inadequate analgesia (pain relief<33% in 1week) and/or unacceptable adverse-events (grade≥3 at Common Terminology Criteria-v4.0). The final sample included 289 participants. To investigate responsible reasons for transdermal-fentanyl intolerance we studied its relation with patients’ history, haematology, biochemistry, body-mass-index, demographic and disease related characteristics. The Eastern Cooperative Oncology Group performance status scale, the Mini Mental State Examination questionnaire, the M.D.Anderson Symptom Inventory and the Greek Brief Pain Inventory were also used to measure performance status and quality-of-life for the same reason. Results: Almost one third of the patients had to change to an alternative opioid oral-morphine in order to achieve adequate analgesia or/and avoid adverse-events. The most common adverse-events observed were nausea/vomiting and sleepiness. Statistical analysis demonstrated that younger age (OR=0.976) and obesity (OR=0.29 against underweight, OR=0.39 against normal, OR=0.48 against pre-obese) had a higher possibility to contribute to modification of the analgesic treatment. Furthermore, a higher impact of symptoms in patient’s life (OR=1.184) and chemotherapy (OR=2.109) could also contribute to the need of change of the opioid analgesic medication. Conclusion: This study found significant variables for transdermal-fentanyl intolerance. This knowledge may help person-center care in moderate to severe cancer pain.   This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/29396
spellingShingle Matina Symeonidi
Irene Panagiotou
Eleni Tsilika
Anna Roumeliotou
Antonis Galanos
Kyriaki Mystakidou
Factors Affecting Opioid Treatment in Cancer Patients
Journal of Pharmacy & Pharmaceutical Sciences
title Factors Affecting Opioid Treatment in Cancer Patients
title_full Factors Affecting Opioid Treatment in Cancer Patients
title_fullStr Factors Affecting Opioid Treatment in Cancer Patients
title_full_unstemmed Factors Affecting Opioid Treatment in Cancer Patients
title_short Factors Affecting Opioid Treatment in Cancer Patients
title_sort factors affecting opioid treatment in cancer patients
url https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/29396
work_keys_str_mv AT matinasymeonidi factorsaffectingopioidtreatmentincancerpatients
AT irenepanagiotou factorsaffectingopioidtreatmentincancerpatients
AT elenitsilika factorsaffectingopioidtreatmentincancerpatients
AT annaroumeliotou factorsaffectingopioidtreatmentincancerpatients
AT antonisgalanos factorsaffectingopioidtreatmentincancerpatients
AT kyriakimystakidou factorsaffectingopioidtreatmentincancerpatients